NantCell, the immuno-oncology arm of Dr. Patrick Soon-Shiong’s sprawling NantWorks umbrella company, has just raised another $57 million, according to a regulatory filing. There are 125 investors listed on this equity raise.
NantCell was launched a year ago, with news of a licensing agreement with Amgen. It acquired the rights to develop and commercialize monoclonal antibody AMG 479, ganitumab, which was previously in Phase 3 development at the biopharma giant. The therapeutic targets Type 1 insulin-like growth factor receptor, which has been a promising cancer therapy target.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In March, it teamed up with San Diego-based Sorrento Therapeutics – acquiring a next-gen version of Abraxane in a deal worth up to $1.3 billion. About $100 million of that was paid as NantCell Equity.
The company’s had two notable fundraises in the past year – $100 million in September, and $75 million in June.
However, NantCell still has no website, and remains as mysterious as most subsidiaries in Soon-Shiong’s healthcare empire. The company has yet to respond to an inquiry regarding the fundraise.
[Photo courtesy of Getty Images]
